暂无介绍

BALB/c mice, 8–10 weeks of age, were intramuscularly vaccinated with either PBS, 1 μg, 3μg or 10 μg MERS-CoV S nanoparticles with or without 5 μg of Matrix-M1™ adjuvant (Novavax AB, Uppsala, Sweden), which has been previously described. Mice were vaccinated at days 0 and 21.On day 30 post-initial vaccination, vaccinated mice were transduced with AdCMVhDPP4 as described previously. Mice were then intranasally inoculated with 2.5×103 pfu of MERS-CoV(Jordan).

暂无介绍

暂无介绍

暂无介绍